Deerfield Management Company, L.P. (Series C) Vincerx Pharma, Inc. Transaction History

Deerfield Management Company, L.P. (Series C)

$5.38 Billion
Q3 2024

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2022 Aug 15, 2022	SELL	$0.0 - $0.0 $0 - $0	-1,379,310 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$0.0 - $0.0 $0 - $0	1,379,310 New	1,379,310 $22.3 Million

Others Institutions Holding VINC

# of Institutions

Shares Held

11M

Call Options Held

Put Options Held

Armistice Capital, LLC New York, NY

2.7M
Shares

$730,080
0.03% of portfolio
Prosight Management, LP Dallas, TX

2.21M
Shares

$595,756
0.43% of portfolio
Sage Rhino Capital LLC

1.7M
Shares

$459,921
0.28% of portfolio
Rock Springs Capital Management LP Baltimore, MD

892K
Shares

$240,764
0.02% of portfolio
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct

674K
Shares

$182,032
0.0% of portfolio

View Full List

About Vincerx Pharma, Inc.

Ticker VINC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 21,189,800
Market Cap $5.72M
Description
Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. Its lead product candidate is VIP152, a cyclin-dependent kinase-9 inhibitor for treating patients with advanced cancer. The company's preclinical stage product candid...

More about VINC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deerfield Management Company, L.P. (Series C), based on Form 13F filings with the SEC.

News

Stay updated on Deerfield Management Company, L.P. (Series C) with notifications on news.

Account